United States· US:70720-022_6a6d50c7-06ea-479c-83cc-f197a9e428c9
MARGENZA
A margetuximab product containing margetuximab, registered in United States by TerSera Therapeutics LLC.
Checked against FDA National Drug Code directory (United States) on
Informational only — not a medical device.
The record
At a glance
FDA National Drug Code directory (United States)- Active substance
- MARGETUXIMAB
- Manufacturer
- TerSera Therapeutics LLC
- Country
- United States (US)
- ATC code
- L01FD06
- ATC class
- Margetuximab
- Reimbursed
- Not published by this register
- Source register
- FDA National Drug Code directory (United States)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L01FD06
Margetuximab, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of FDA National Drug Code directory (United States). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/fd624dde-940f-4f66-82a5-e154fd3d892f GET /v1/drugs/fd624dde-940f-4f66-82a5-e154fd3d892f?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"route": "INTRAVENOUS",
"source": "ndc",
"strength": "25",
"substance": "MARGETUXIMAB",
"productndc": "70720-022",
"dosage_form": "INJECTION, SOLUTION, CONCENTRATE",
"dea_schedule": null,
"strength_unit": "mg/mL",
"application_number": "BLA761150",
"marketing_category": "BLA"
}See everything about margetuximab.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.